PURPOSE: Ocular lubricants are a foundational element in the symptomatic management of dry eye disease (DE). Blink Triple Care (BTC) is a benzalkonium chloride-free, over-the-counter eye drop that features a tri-action mechanism of relief, combining hyaluronic acid for hydration, nano-emulsion lipids for tear film stabilization, and osmoprotectants for cellular protection. This comprehensive formulation is designed to address both evaporative and aqueous-deficient subtypes of DE by enhancing tear film integrity, locking in moisture, and reducing tear evaporation. This study aimed to evaluate real-world patient-reported outcomes and satisfaction following short-term use of BTC in habitual artificial tear users.

METHODS: This was a prospective cross-sectional survey study of self-identified dry eye sufferers. Adult DE sufferers in the US were recruited from a nationally representative consumer panel. Eligible participants had used over-the-counter artificial tears/lubricants in the prior 6 months, with confirmed DE symptoms documented by ocular surface disease index (OSDI) scores at screening. Participants who had undergone ocular surgery within 6 months or were allergic to any formulation of eye drops were excluded. Enrolled participants received an unbranded bottle of BTC with instructions to administer a drop(s) in the morning. Participants then completed questionnaires at four timepoints: immediately, then 4, 8, and 10 hours after instillation. The survey measured patient reported outcomes including global symptoms, a set of DE-specific symptoms and treatment satisfaction.

RESULTS: A total of 621 participants screened were assigned to use BTC (56% female; 73% aged 25–64 and 25% ≥65). OSDI scores indicated mild, moderate or moderate/severe DE in 32.9%, 34.6% and 32.5% of participants, respectively. Participants reported immediate feelings of comfort and relief after using BTC (agree/strongly agree: Comfortable 87%, Hydrating 86%, Soothing 81%, Relieving 81%), and these agreement rates were consistent at 4-, 8-, and 10-hour timepoints. When patients with available data were stratified by OSDI, mild, moderate, and moderate/severe sufferers reported similarly high levels of agreement with key performance attributes immediately after use: "my dry eyes feel better", 89%, 84%, and 85%, respectively; "my dry eye symptoms are improved", 83%, 73%, and 74%, respectively; "my dry eyes feel relieved", 87%, 75%, and 75%, respectively. These agreement rates were sustained at the 4-, 8-, and 10-hour timepoints.

CONCLUSION: These real-world findings highlight the immediate and enduring relief from DE symptoms provided by BTC drops. These improvements in hydration, moisturization, comfort, and symptom relief were achieved across OSDI-assessed severity, indicating the real-world benefit to patients with DE, regardless of symptom severity.